Seizures are among the most common neurologic events that occur among people with HIV, but there is little epidemiologic data available to guide clinical decision-making regarding whether or when to initiate long term antiepileptic drug (AED) treatment for HIV+ individuals who experience a first seizure. In Zambia, where epilepsy and AIDS prevalence rates are both high and only enzyme-inducing AEDs are routinely available, the risk of interactions between AEDs and antiretroviral medications (ARVs) is especially concerning. This Zambian-based prospective cohort study of HIV+ adults who have experienced new onset seizure will provide important insights into seizure recurrence rates and risk factors for future seizures in people with HIV/AIDS. Knowledge gained from this work will assist clinicians in determining when/whether to initiate chronic treatment for seizures. This project will also expand the capacity for epidemiologic studies of neurologic disorders among people with HIV/AIDS in Zambia and lay the groundwork for the conduct of future research aimed at determining whether the co-usage of enzyme-inducing AEDs and ARVs predispose patients to ARV drug failure and potentially increase the risk of drug resistant HIV.

Public Health Relevance

As antiretroviral treatments become broadly available in Africa, HIV is evolving from a fatal infection into a chronic condition. Caring for people with HIV/AIDS who also suffer from other chronic health conditions, such as epilepsy, is challenging because clinicians do not have sufficient knowledge to know what treatments are best when these disorders co-occur. This prospective study of HIV+ Zambian adults will provide us with important insights into when chronic treatment for seizure prevention is needed and develop the research expertise and foundational knowledge to determine, in future studies, whether combining antiretroviral medications with the older generation epilepsy medications still used in most resource poor settings increases the risk of antiretroviral drug failure.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ICP2-B (51))
Program Officer
Fureman, Brandy E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Michigan State University
Schools of Osteopathic Medicine
East Lansing
United States
Zip Code
Elafros, Melissa A; Birbeck, Gretchen L; Gardiner, Joseph C et al. (2017) Patient-Reported Adverse Effects Associated with Combination Antiretroviral Therapy and Coadministered Enzyme-Inducing Antiepileptic Drugs. Am J Trop Med Hyg 96:1505-1511
Siddiqi, Omar K; Elafros, Melissa A; Bositis, Christopher M et al. (2017) New-onset seizure in HIV-infected adult Zambians: A search for causes and consequences. Neurology 88:477-482
Sikazwe, I; Elafros, M A; Bositis, C M et al. (2016) HIV and new onset seizures: slipping through the cracks in HIV care and treatment. HIV Med 17:118-23
Siddiqi, Omar K; Elafros, Melissa A; Sikazwe, Izukanji et al. (2015) Acute EEG findings in HIV-infected Zambian adults with new-onset seizure. Neurology 84:1317-22
Kalungwana, Lisa; Elafros, Melissa A; Siddiqi, Omar K et al. (2014) Cognitive impairment and psychiatric morbidity in HIV+ Zambians with new-onset seizure. Am J Trop Med Hyg 91:1254-8
Potchen, Michael J; Siddiqi, Omar K; Elafros, Melissa A et al. (2014) Neuroimaging abnormalities and seizure recurrence in a prospective cohort study of zambians with human immunodeficiency virus and first seizure. Neurol Int 6:5547
Birbeck, Gretchen L (2014) Careers in global neurology. Ann Neurol 75:805-9
Siddiqi, Omar K; Koralnik, Igor J; Atadzhanov, Masharip et al. (2013) Emerging subspecialties in neurology: global health. Neurology 80:e78-80
Siddiqi, Omar; Birbeck, Gretchen L (2013) Safe Treatment of Seizures in the Setting of HIV/AIDS. Curr Treat Options Neurol 15:529-43
Siddiqi, Omar K; Atadzhanov, Masharip (2013) Neurological letter from Zambia. Pract Neurol 13:281-5